相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
100.0%
暂无批准数据
- Korea's KDCA issued an influenza advisory effective midnight on the 11th after cases reached 25.3 per 1,000 outpatients, about twice the 12.9 epidemic threshold. - The outbreak arrived earlier than usual, with the rate climbing from 7.5 to 9.2, 13.3 and 25.3 over four weeks and hospitalizations up roughly 13-fold year over year. - Influenza A(H1N1)pdm09 is the dominant strain and matches this season's vaccine, with no antiviral resistance mutations detected, while COVID-19 admissions rose for a sixth week. - State vaccination begins on the 21st for children and pregnant women, with high-risk groups able to receive insurance-covered antivirals without a separate diagnostic test.
- South Korea's Ministry of Health and Welfare approved a first-phase health insurance coverage expansion plan expected to benefit approximately 1.97 million people with up to 800 billion won annually. - The special co-payment rate for roughly 1.36 million patients with rare or serious incurable diseases will fall from 10% to 7% this December, then to 5% in the first half of 2028. - Coverage for severe diabetes will expand from type 1 to type 2, extending insulin pump and continuous glucose monitor benefits to about 11,000 additional patients. - Fintepla, a treatment for Dravet syndrome, will gain insurance coverage, cutting annual patient costs from roughly 100 million won to about 10 million won.
- The Korea Medical Tourism Promotion Association (KMTPA) and Yanolja Research signed an MOU to jointly promote South Korea's medical and wellness tourism industry. - The partnership aims to combine Yanolja Research's travel data capabilities with KMTPA's field network to develop data-driven regulatory reform proposals. - Forum participants called for updating medical advertising rules, which they say have not kept pace with foreign patients' shift to digital channels. - The initiative seeks to link medicine, wellness, accommodation, and tourism into a single ecosystem to extend foreign visitors' stays and boost spending.
- Taiwan reclassified etomidate as a Category 1 narcotic on June 27, 2026, making the death penalty the maximum punishment for its manufacture, transportation, and sale. - Drug-impaired driving cases in Taiwan surged from 2,619 in 2024 to 8,659 in 2025, with etomidate detected in approximately 20% of drivers in 2026. - Etomidate-related deaths reached 92 in 2025, the highest among all new psychoactive substances, accounting for roughly 60% of such fatalities. - The drug's rapid spread is fueled by low production costs, easy integration into e-cigarette liquids, and difficulty of detection by law enforcement.
- Roche will invest 710 billion won ($520 million) over five years to conduct major clinical trials for new drug development in South Korea, marking the first time the Korean Ministry of Health and Welfare has secured such a substantial investment from a foreign pharmaceutical company. - The Swiss pharmaceutical giant approached Korea first after evaluating the country's clinical trial capabilities, citing fast patient recruitment, high data quality, and well-trained clinical trial personnel including research nurses. - The partnership will focus on global clinical trials for high-prevalence and intractable diseases as well as advanced biopharmaceuticals, while supporting R&D talent development and identifying promising biotech firms through open innovation initiatives. - The Korean government aims to leverage this agreement to develop South Korea into a global clinical trial hub in Asia, enhancing the country's clinical trial competitiveness and supporting domestic bio-health companies' global expansion.
- Ybrain has launched MINDD STIM+ Pro, an upgraded version of Korea's first at-home electronic medicine for depression treatment, featuring enhanced capacity and accessibility. - Clinical trials at six Korean medical institutions demonstrated a 62.8% remission rate for major depressive symptoms and 47.74% improvement in depression scores. - The new system triples module capacity to six units and increases consumables tenfold, enabling hospitals to treat more patients simultaneously while supporting digital transformation. - The device delivers mild electrical current to the brain through a headband-like apparatus for 30 minutes daily over six weeks, with regulatory approval completed.
- Barbadian authorities officially recognized positive results from a pilot study of Biorat, a biological rodenticide developed by Cuban biotechnology company Labiofam. - The field trial was conducted in urban areas of Barbados under the leadership of Labiofam researchers in collaboration with local health authorities. - Officials from multiple Barbadian ministries, the UN World Food Programme, and academic institutions participated in acknowledging the project's success. - Biorat represents an ecological and sustainable alternative for pest control, demonstrating the potential for strengthened scientific cooperation between Cuba and Barbados.
- Taiwan's Intellectual Property and Commercial Court upholds strict interpretation of patent term extensions, ruling that a 54-day delay in drug approval collection was attributable to the applicant. - The court established that delays in pharmaceutical patent extensions must be justified by objective factors comparable to natural disasters or war, not routine regulatory communications. - The landmark decision impacts how pharmaceutical companies must approach drug approval processes, emphasizing the importance of timely submission and collection of approvals.
- Chonnam National University Hwasun Hospital and VaxCell Biotherapeutics receive approval for advanced regenerative medicine study combining NK cell therapy VCB-1102 with standard chemotherapy for pancreatic cancer. - VCB-1102 demonstrated impressive results in recent liver cancer trials, achieving a 68.75% objective response rate and 100% disease control rate with median progression time of 16.82 months. - The new study will evaluate VCB-1102 combined with mFOLFIRINOX chemotherapy in 22 advanced pancreatic cancer patients, addressing a critical need in a disease with less than 10% five-year survival rate.
